KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aquestive Therapeutics (AQST) Preferred Shares (2017)

Aquestive Therapeutics has reported Preferred Shares over the past 1 years, most recently at $16.9 million for Q4 2017.

  • Quarterly results put Preferred Shares at $16.9 million for Q4 2017, changed N/A from a year ago — trailing twelve months through Dec 2017 was $16.9 million (changed N/A YoY), and the annual figure for FY2017 was $16.9 million, changed.
  • Preferred Shares for Q4 2017 was $16.9 million at Aquestive Therapeutics.
  • Over the last five years, Preferred Shares for AQST hit a ceiling of $16.9 million in Q4 2017 and a floor of $16.9 million in Q4 2017.